This observational trial (n=13) was conducted by the University Hospital, Strasbourg, France. The study aimed to assess the tolerance and potential synergistic effect of combining intranasal esketamine with non-selective MAOIs in patients with depression and anxiety disorders.
Published data on combinations of ketamine/esketamine with MAOIs are sparse and to our knowledge no data exist for intranasal esketamine; this study shares clinical experience from a specialised centre.
Retrospective case-only series of 13 adults treated with intranasal esketamine between 2018-01-01 and 2022-03-01 assessing tolerability and potential synergistic effects when combined with non-selective MAOIs; data reuse required patient consent.